Table 1

Transparency Index: ranking of new drugs according to the ethics standard that all trial results should be publicly available to contribute to generalisable knowledge

Drug*CompanyIndicationNumber of trials analysed from FDA* approval packagePercentage of trials registeredPercentage of trials reportedPercentage of trials publishedPercentage of trial results that are publicly available (reported or published)
StribildGileadHIV342492121
AubagioSanofiMultiple sclerosis3234191622
ElelysoPfizer & ProtalixGaucher disease5100204040
ZaltrapSanofiColorectal cancer3040303740
StivargaBayerColorectal cancer1275174242
EliquisBMSAnticoagulant3926104444
ZioptanMerck & SantenEye pressure, glaucoma1625134444
XeljanzPfizerRheumatoid arthritis3482535665
BosulifPfizerLeukaemia17100247171
PerjetaGenentech/RocheBreast cancer125087575
SigniforNovartisCushing’s disease1729128282
ErivedgeGenentech/RocheBasal cell carcinoma1283258383
InlytaPfizerRenal cell carcinoma286146100100
SirturoJanssen (J&J)Tuberculosis14572193100
MenHibrixGSKMeningitis vaccine, children16100100100100
Median1757205665
IQR13–3132–8312–2841–8341–83
  • *For a list of the active ingredients for these drugs (see online supplementary appendix 2).